ZTI BIOSCIENCES

TERACARRIER

|

The TERACARRIER functions as an all-integrative Radiopharmaceutical Platform for any existing Radioligands & Isotopes. It is the first & only technology in the world that can fully bind-lock the radioisotopes, with the targeting ligands, within the iron-oxide nano-particle based core. Unlike conventional chelators/linkers, ZTI’s carrier physically locks the radioisotopes within, TERACARRIER based drugs are immune to chemical leeching of radioisotopes within the body. This tech will improve the targeting rate of radiopharmaceuticals and prevent off-target side effects from free isotopes broken off the drugs.

|

Nano-tech built iron-oxide core is capable of physically imprisoning any type of numerous isotopes within removing the issue of free radioisotopes after injection. The LNP shell that covers the core is applicable with any existing commercial targeting ligands. A single carrier can hold numerous isotopes & ligands, and yet still within the size of only 4.5nm.

|

ZTI tech will standardize the development of radiopharmaceuticals, bringing exponential versatility in indications and pipelines, providing a symbiotic platform for every existing oncological Radioligand Therapy. 

Mag-I

|

Mag-I is a therapeutic radiopharmaceutical that utilizes Iodine-131 isotopes as payloads and Folate as targeting agents. With ZTI’s original Tech, now iodine therapy is no longer limited to thyroid cancers but applicable to all kinds of solid cancers in oncology.

|

Utilizing pre-approved components

Prescribers(MDs) can be assured of safety because all the components of the Mag-I are FDA approved & already used routinely in clinical trials. Even after the FDA approval, a new drug still needs to be selected by prescribers. A new drug must be safe enough, to ensure the established MDs, that there is no risk to their careers in using the drug. 

Zhyper-X

|

Overview

Radiopharmaceutical Synthesis Technology, enabling the field synthesis at hospitals by miniaturization & automation of the drug producer machine.

|

Feature

Zhyper-X is a fully automated Radiopharmaceutical synthesizer that can manufacture and package nuclear medicine. This allows the radiopharmaceuticals to be administered within 24 hours from production by the technology enabling the field synthesis at hospitals by miniaturization & automation of the drug producer machine. ZTI’s Radiopharmaceutical Synthesis Technology will bring the best solution to the short half-life of nuclear medicine.

|

Field Synthesis

With ZTI’s cold-type drug & radioisotopes ready supplied, the Zhyper-X can produce and purify to produce ready-to-go radiopharmaceuticals within 24hours. This will allow us access to the best to the counter strategy against the short half-life issue of radioisotope therapy.

With Zhyper-X installed in designated hospitals, we can remove the lead time that is spent with facility manufacturing + packaging + delivery. The Delivery alone, after manufacturing and packaging is done, is expected to take at least 3-4days minimum. But with the field synthesis technology available, we can directly ship the isotopes to the Zhyper-X installed hospitals to have the radioisotopes ready in 24 hours. Just have to drug carriers ready and isotopes delivered a day before, by the time that patient arrives for the administration, the nuclear medicine will have 90% of it’s efficacy still intact.